Elanco Animal Health, primarily owned by institutional investors, specializes in products for pets and farm animals, including vaccines and therapeutics. Analysts have mixed ratings on the stock, with a consensus "Hold" and a price target averaging $16.75, while recent earnings showed a slight revenue decline year-over-year. The company has a market cap of $6.18 billion and reported a quarterly EPS of $0.13, surpassing estimates.